PrecisioBiotix is creating precision biologial antibacterials with an emphasis on topical diseases. Subsidiary companies are: (1) Lysigen, which develops first or best-in-class lysins; and (2) Phagelux, which develops sustained release topical solutions.

  • Lysigen

    Treating multiple bacterial conditions utilizing first or best-in-class lysins. Lead products are for the treatment of eczema and acne. See further  www.lysigen.com.

    >More

     

    Phagelux 

    Preventing and treating AMR resistant topical infections utilizing novel sustained release phage spray and patch systems.

    Lead product is for the prevention of AMR infections. See further www.phagelux.com

    >More

  • Antibiotic Resistance - The Need for New Treatments

    According to WHO, if we do not take significant action, we will enter a post-antibiotic era in which a common infection and minor injury can be life-threatening. It is estimated that by 2050 more people will die from infection than from cancer.

     

       

     

    >More

  •     Contact Us

          PrecisioBiotix

          Contact person: Aileen Shen

      Tel: 19941606303

      Email: shencj@precisiobiotix.com